|
Canada-0-Propellers Azienda Directories
|
Azienda News:
- Connecting the Dots: NTRK-driven lung cancer
For NTRK-positive lung cancer patients, the results were encouraging, with many experiencing rapid and durable responses As progress continued, attention turned to resistance In 2021, Dr Drilon and Dr Emiliano Cocco identified a new resistance mechanism publishing their findings in prestigious Nature Medicine
- NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy . . .
The detection of NTRK gene fusion is recommended by the National Comprehensive Cancer Network (NCCN) clinical practice guidelines, and the TRK inhibitors (larotrectinib and entrectinib) are preferred as the first-line treatment for locally advanced or metastatic patients with NTRK-fusion-positive NSCLC (8)
- NTRK and Lung Cancer - American Lung Association
NTRK is an important biomarker that can impact lung what treatment options Dr Robert Doebele explains what an NTRK gene fusion is in cancer NTRK is an important biomarker that can impact lung what treatment options The videos above were produced in 2020 For the latest treatment options, speak with your doctor
- What is NTRK positive (NTRK+) Lung Cancer?
If you have non-small cell lung cancer and your tumor tested positive for the NTRK biomarker, you have NTRK+ (NTRK positive) lung cancer This fact sheet explains what this means and how it may affect lung cancer treatment WHAT IS NTRK? NTRK (neurotrophic tyrosine receptor kinase) is a gene that can can move or fuse to another gene
- NTRK Fusion-positive Non–small-cell Lung Cancer: The . . .
Introduction Lung cancer is the leading cause of cancer-related death worldwide 1 The therapeutic strategy of non–small-cell lung cancer (NSCLC) has changed significantly with the advent of molecular-targeted therapy targeting driver oncogenes Approximately one-third of patients with NSCLC have a therapeutically targetable driver oncogene, which expands the treatment options and leads to
- NTRK gene fusion testing and management in lung cancer
This review highlights the importance of testing for NTRK gene fusions in lung cancer, ideally using the gold-standard method of RNA-based NGS, the various assays that are available, and treatment algorithms for patients
- NTRK Therapy among Different Types of Cancers, Review and . . .
NTRK therapy has emerged as a promising treatment option for cancer patients with NTRK fusion-positive tumors Following the landmark NAVIGATE clinical trials, the development of first- and second-generation NTRK inhibitors transformed the treatment landscape, providing superior clinical outcomes, greater quality of life, and longer survival
- Updated efficacy and safety of entrectinib in - Lung Cancer
NTRK fusions result in constitutively active oncogenic TRK proteins responsible for ∼ 0 2 % of non-small cell lung cancer (NSCLC) cases Approximately 40 % of patients with advanced NSCLC develop CNS metastases; therefore, treatments with intracranial (IC) efficacy are needed
- Science Made Simple: drug approval for NTRK - Lung Cancer . . .
What it means for patients Larotrectinib is an effective treatment for NTRK fusion positive NSCLC It is important to note that NTRK fusions are present in many tumors other than lung cancer – including thyroid, gastrointestinal, central nervous system, and salivary gland cancers as well as sarcomas and pediatric cancers
- Efficacy and Safety of NTRK Inhibitors in Patients With NTRK . . .
Can you discuss treatment of NTRK fusion–positive lung cancer according to stage? Dr Drilon: In the stage IV setting, the targeted therapies larotrectinib and entrectinib really beat everything else in terms of response and durability They are our best drugs for patients with NTRK fusions, and they should be used up front whenever possible
|
|